REFERENCES
- Becker FF, Broome JD. L-Asparaginase—inhibition of early mitosis in regenerating rat liver. Science. 1967;156: 1602–1603.
- Becker FF, Broome JD. L-Asparaginase-inhibition of endogenous RNA polymerase activity in regenerating liver. Arch Biochem Biophys. 1969 Mar;130(1): 332–336.
- Asselin BL, Whitin JC, Coppola DJ, Comparative pharmacokinetic studies of 3 asparaginase preparations. J Clin Oncol. 1993;11:1780–1786.
- Boos J, Werber G, Ahlke E, Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32A:1544–1550.
- Avramis VI, Sencer S, Periclou AP, A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986–1994.
- Albertsen BK, Jakobsen P, Schroder H, Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemother Pharmacol. 2001;48:77–82.
- Ahlke E, Nowak Gottl U, Schulze Westhoff P, Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997;96:675–681.
- Hempel G, Muller HJ, Lanvers-Kaminsky C, A population pharmacokinetic model for PEGylated-asparaginase in children. Br J Haematol. 2010;148:119–125.
- Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol. 2007;29:239–247.
- Pieters R, Appel I, Kuehnel HJ, Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008;112:4832–4838.
- Lanvers C, Pinheiro JPV, Hempel G, Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem. 2002;309:117–126.
- Jonsson EN, Karlsson MO. Xpose—an S-PLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58: 51–64.
- Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic pharmacodynamic models. 1. Models for covariate effects. J Pharmacokinet Biopharmaceut. 1992;20:511–528.
- Schrappe M, Reiter A, Ludwig WD, Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310–3322.
- Schrappe M, Reiter A, Zimmermann M, Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 2000;14:2205–2222.
- Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28:97–113.
- Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG. L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 1981;41:4554–4558.
- Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 1999.
- Ette EL, Williams PJ, Kim YH, Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610–623.
- Schrey D, Borghorst S, Lanvers-Kaminsky C, Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer. 2010;54:952–958.